📰 Accelerated Approval Program News
Page 3 - Accelerated Approval Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Accelerated Approval Program. Real-time updates on events, politics, business and more.
January 25, 2023
After another insightful conference this year, these are some of the key legal deal trends to expect from the health care and life sciences industries in 2023.
December 30, 2022
Sarah Silbiger/Getty Images, FILE(WASHINGTON) -- A congressional investigation into the Food and Drug Administration's review process for an Alzheimer's treatment found that the agency "deviated" from its standard procedures to approve the Aduhelm drug with inconsistent data. Aduhelm is notable for being the first drug in recent years approved to treat the underlying cause of Alzheimer's, a disease with no known cure that is characterized by progressive dementia that aff...
December 29, 2022
The Food and Drug Administration's review process for an Alzheimer's treatment found that the agency "deviated" from its standard procedures to approve the Aduhelm drug.
November 10, 2022
Significant Necrosis Demonstrated in Invasive Ductal and Lobular Cancers, Which are Normally Resistant to Chemotherapy. Significant Necrosis from a Single...
October 20, 2022
Cui bono is Latin for "Who benefits?" Its the sister phrase of "sequi pecuniam/follow the money" and the orphan of "plebes/the people." All roads used to lead to Rome. Today, they lead to chosen industry. There are many sayings about...
September 10, 2022
/PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that...
August 30, 2022
Novartis Scemblix®, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia
June 24, 2022
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least
June 24, 2022
The US FDA has granted accelerated approval to Novartis’ combination therapy Tafinlar (dabrafenib) + Mekinist (trametinib) to treat solid tumours.
June 23, 2022
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors